DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213089

Correlation of the expression of estrogen receptor, progesterone receptor and HER2/neu with the clinical features and the tumour histopathology in patients of breast carcinoma at mahavir cancer sansthan

Kumari B. Lata, Surya K. Nirala

Abstract


Background: Breast carcinoma is the most common malignant tumor and the leading cause of cancer death in women, with more than 10,00,000 cases occurring worldwide annually. Its incidence varies from one geographical area to the other.

Methods: Cases of all breast conservative surgeries and modified radical mastectomy specimen received for routine histopathological evaluation from the department of onco Surgery, Mahavir Cancer Sansthan, Patna, Bihar, form the source of data for the study.

Results: Infiltrating duct cell carcinoma (NOS) type was the commonest type of carcinoma breast in our institute with significant group occurring in more than 45 years of age. ER and PR positive expression was seen in grade 2 tumors and negative expression was seen with tumor size more than 2cm, positive lymph nodes and higher stage of disease. HER2/neu negative expression was seen in the post-menopausal age group, tumor size more than 2 cm, positive lymph nodes and higher stage of disease indicating bad prognosis. HER2/neu expression was inversely related to ER and PR expression. HER2/neu expression was seen in 50% of medullary carcinoma which is rare. Triple negative cases were seen in 22.08% cases of infiltrating duct cell carcinoma indicating bad prognosis.

Conclusions: A beforehand knowledge of these immunohistochemical markers can help oncotherapists to initiate a correct form of treatment and improve the survival rate in breast carcinoma patients.


Keywords


Breast carcinoma, ER, PR, HER2/NEU

Full Text:

PDF

References


Rosai RJ, Ackermans surgical pathology. St Louis: Elsevier; 2011: 1660-1712.

Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007;31(5):1031-40.

National Cancer Registry Programme. Consolidated report of PBCRs: 1990-1996. New Delhi: Indian Council of Medical Research; 2001.

Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146-51.

Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):966-78.

Raina V, Bhutani M, Bedi R, Sharma A, Deo SV, Shukla NK, et al. Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Ind J Canc. 2005;42(1):40-5.

Raina V, Bhutani M, Bedi R, Sharma A, Deo SV, Shukla NK, Mohanti BK, et al. Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Ind J Canc. 2005;42(1):40-5.

McDivtt RW, Anderson WAD. Breast. In: Kissane JM, eds. Andersons Pathology. 8th ed. St. Louis: Mosby Company; 1985: 1546-1569.

Nadji M, Fernandez C, Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21-7.

Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10(7):1049-56.

Bodai BI, Tuso P. Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical ssues and Lifestyle Recommendations. Perm J. 2015;19(2):48-79.

Devi PU, Prasad U, Lakshmi AB, Rao GS. A study of correlation of expression of ER, PR and HER2/NEU recptor status with clinic-pathological parameters in breast carcinoma at a tertiary care centre. IJRMS. 2015;1:165-73.

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol. 2008;6:112.

Raina V, Bhutani M, Bedi R, Sharma A, Deo SV, Shukla NK, et al. Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Indian J Cancer. 2005;42(1):40-5.

Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani, Murthy NS. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India--a cross-sectional study. World J Surg Oncol. 2005;3:67.

Lokuhetty MD, Ranaweera GG, Wijeratne MD, Wickramasinghe KH, Sheriffdeen AH. Profile of breast cancer in a group of women in a developing country in South Asia: is there a difference? World J Surg. 2009;33(3):455-9.

Mudduwa LK. Quick score of hormone receptor status of breast carcinoma: correlation with the other clinicopathological prognostic parameters. Indian J Pathol Microbiol. 2009;52(2):159-63.

Ahmad Z, Khurshid A, Qureshi A, Idress R, Asghar N, Kayani N. Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and nottingham prognostic index scoring on mastectomy specimens. Indian J Pathol Microbiol. 2009;52(4):477-81.

Yadav R, Sen R, Chauhan P. ER, PR, HER2/NEU status and relation to clinicopathological factors in breast carcinoma. IJPPS. 2016;8(4):975.

Manjunath S, Prabhu JS, Kaluve R, Correa M, Sridhar TS. Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype?. Indian J Surg Oncol. 2011;2(2):122-5.